Vicki L. Seyfert-Margolis
Food and Drug Administration
Senior Advisor for Science Innovation and Policy
VICKI L. SEYFERT-MARGOLIS, PhD is Senior Advisor within Science Innovation and Policy for the FDA Commissioner’s Office. Dr. Seyfert-Margolis focuses on initiatives in regulatory science, personalized medicine and scientific computing and informatics. Previously, she served as Chief Scientific Officer at Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, she oversaw the development of more than 20 centralized laboratory facilities, and the design and execution of biomarker discovery studies for over 25 Phase II clinical trials. As part of the biomarker efforts she established construction of a primer library of 1,000 genes that may be involved in establishing and maintaining immunologic tolerance and co-discovered genes that may mark kidney transplant tolerance. Dr. Seyfert-Margolis was also an Adjunct Associate Professor with the Department of Medicine at the University of California San Francisco. Prior to academia, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine. Dr. Seyfert-Margolis co-authored an article in The New England Journal of Medicine July 15, 2010 issue titled Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.